Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORM-12741 for agitation and aggression in Alzheimer's disease
2014-000217-30Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ORM-12741 in Alzheimer's disease (AD) (3 arms), sponsored by Orion Corporation. Primary endpoint: Sum of NPI-C agitation and aggression domains. Started Mar 2015; status: completed.
02
Drugs
ORM-12741
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2014-000217-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000217-30.